425 related articles for article (PubMed ID: 8791046)
21. Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Goepel M; Tscholl R
Br J Urol; 1998 Apr; 81(4):532-8. PubMed ID: 9598623
[TBL] [Abstract][Full Text] [Related]
22. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
Goel T; Garg S
Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
[TBL] [Abstract][Full Text] [Related]
23. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
25. Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy.
Janbaziroudsari H; Mirzaei A; Maleki N
Bull Cancer; 2016 Sep; 103(9):730-4. PubMed ID: 27345449
[TBL] [Abstract][Full Text] [Related]
26. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
27. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
van Vuuren SP; Heyns CF; Zarrabi AD
BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
[TBL] [Abstract][Full Text] [Related]
28. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
29. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
30. Relationship between Prostatic Specific Antigen (PSA) and volume of the prostate in the Benign Prostatic Hyperplasia in the elderly.
Bo M; Ventura M; Marinello R; Capello S; Casetta G; Fabris F
Crit Rev Oncol Hematol; 2003 Sep; 47(3):207-11. PubMed ID: 12962896
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer.
Castaldo G; Cecere G; di Fusco V; Prezioso D; d'Armiento M; Salvatore F
Clin Chim Acta; 1997 Sep; 265(1):65-76. PubMed ID: 9352130
[TBL] [Abstract][Full Text] [Related]
32. [Prostate specific antigen and diagnosis of prostate cancer].
Rigaud J; Bouchot O
Rev Prat; 2003 Dec; 53(20):2229-36. PubMed ID: 15018076
[TBL] [Abstract][Full Text] [Related]
33. Influence of high-grade prostatic intra-epithelial neoplasia on total and percentage free serum prostatic specific antigen.
Morote J; Encabo G; Lopez M; de Torres IM
BJU Int; 1999 Oct; 84(6):657-60. PubMed ID: 10510111
[TBL] [Abstract][Full Text] [Related]
34. Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer.
Schambeck CM; Schmeller N; Stieber P; Jansen HM; Pahl H; Schneider W; Fateh-Moghadam A
Urology; 1995 Aug; 46(2):195-9. PubMed ID: 7542821
[TBL] [Abstract][Full Text] [Related]
35. Optimum PSA reflex-range.
Benecchi L
Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
[TBL] [Abstract][Full Text] [Related]
36. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic significance of prostate-specific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems.
Manseck A; Pilarsky C; Froschermaier S; Menschikowski M; Wirth MP
Urol Int; 1998; 60(1):25-7. PubMed ID: 9519417
[TBL] [Abstract][Full Text] [Related]
38. Effect of prostatic massage on serum complexed prostate-specific antigen levels.
Tarhan F; Orçun A; Küçükercan I; Camursoy N; Kuyumcuoğlu U
Urology; 2005 Dec; 66(6):1234-8. PubMed ID: 16360449
[TBL] [Abstract][Full Text] [Related]
39. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Magklara A; Scorilas A; Catalona WJ; Diamandis EP
Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
[TBL] [Abstract][Full Text] [Related]
40. Prostate tissue and serum markers.
Mazzucchelli R; Colanzi P; Pomante R; Muzzonigro G; Montironi R
Adv Clin Path; 2000 Jul; 4(3):111-20. PubMed ID: 11080790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
